Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04933994
  4. Details
NCT04933994 Clinical Trial

Comparison of COVID-19 and H1N1 Influenza Pneumonia

COVID-19 Clinical Trial

Official title:
Comparison of the Clinical and CT Features Between COVID-19 Pneumonia and H1N1 Influenza Pneumonia in Zhejiang, China

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04933994
Other study ID # 2021-0187
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2017
Est. completion date September 15, 2020

Study information
Verified date October 2020
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To explore the different clinical and CT features distinguishing COVID-19 from H1N1 influenza pneumonia.

Description:

COVID-19 pneumonia patients showed less proportions of underlying diseases, fever and respiratory symptoms than those of H1N1 pneumonia patients (p<0.01). White blood cell count, neutrophilic granulocyte percentage, C-reactive protein, procalcitonin, D-Dimer and lactate dehydrogenase in H1N1 pneumonia patients were higher than those of COVID-19 pneumonia patients (p<0.05). H1N1 pneumonia were often symmetrically located in the dorsal part of lung inferior lobes, while COVID-19 pneumonia were unsually showed a peripheral but non-specific lobe distributions. Ground glass opacity was more common in COVID-19 pneumonia and consolidation lesions was more common in H1N1 pneumonia (p<0.01). COVID-19 pneumonia lesions showed a relative clear margin compared with H1N1 pneumonia. Crazy-paving pattern, thickening vessels, reversed halo sign and early fibrotic leisions were more common in COVID-19 pneumonia than H1N1 pneumonia (p<0.05). Pleural effusion in COVID-19 pneumonia was significantly less common than H1N1 pneumonia (p<0.01). Compared with H1N1 pneumonia in Zhejiang, China, the clinical manifestations of COVID-19 pneumonia was more concealed with less underlying diseases and slighter respiratory symptoms. The more common CT manifestations of COVID-19 pneumonia included ground glass opacity with a relative clear margin, crazy-paving pattern, thickening vessels, reversed halo sign and early fibrotic leisions, while the less common CT manifestations of COVID-19 pneumonia included consolidation and pleural effusion.

Recruitment information / eligibility
Status Completed
Enrollment 483
Est. completion date September 15, 2020
Est. primary completion date February 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - pneumonia Exclusion Criteria: - no pneumonia

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• computed Tomography
All cases were detected with computed Tomography

Locations
Country Name City State
n/a

Sponsors (9)
Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University Kecheng People's Hospital of Quzhou city, Zhejiang Province, Pingyang People's Hospital of Zhejiang Province, Ruian People's Hospital of Zhejiang Province, Taizhou Hospital of Zhejiang Province, The First Hospital of Jiaxing, Zhejiang Province, The First People's Hospital of Yuhang District, Hangzhou, Zhejiang Province, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Yueqing People's Hospital of Zhejiang Province

Outcome
Type Measure Description Time frame Safety issue
Primary Comparison of the clinical and CT features between COVID-19 pneumonia and H1N1 influenza pneumonia in Zhejiang, China one paper 1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Active, not recruiting NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure